Stock 4D PHARMA PLC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases 4d Pharma PLC London S.E.

Equities

GB00BJL5BR07

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
4D pharma : Announces Two Presentations at The Society for Immunotherapy of Cancer Annual Meeting (SITC 2022) - Form 6-K
PU
4D pharma : Presents at The Society for Immunotherapy of Cancer Annual Meeting (SITC 2022)
PU
4D pharma : Announces Two Presentations at The Society for Immunotherapy of Cancer Annual Meeting (SITC 2022) - Form 6-K
PU
4D pharma : Announces Two Presentations at The Society for Immunotherapy of Cancer Annual Meeting (SITC 2022)
PU
4D pharma : Publication of Joint Administrators’ Proposals - Form 6-K
PU
4D PHARMA : “4D pharma”) RECEIVES NOTICE OF DELISTING FROM NASDAQ - Form 6-K
PU
4D pharma plc (“4D pharma”) Receives Notice of Delisting From Nasdaq
BU
Update on Suspension of Trading
BU
4D pharma presents trial in progress poster on the Phase II Study of MRx0518 in combination with BAVENCIO(R) in patients with unresectable locally advanced or metastatic urothelial carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
BU
4D pharma to Present at the H.C. Wainwright Global Investment Conference
BU
4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International Conference
BU
4D pharma : Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022 - Form 6-K
PU
4D pharma : Annual Report and Account for the year ended 31 December 2021
PU
4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022
BU
4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA (pembrolizumab) for the Treatment of Renal Cell Carcinoma
AQ
4D pharma : Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma - Form 6-K
PU
4D pharma : Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma
PU
4D pharma : Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma
PU
4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines Summit
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DDDD Stock
  4. Stock
  5. News 4d Pharma PLC
  6. Press Releases